Clinical Trials Browser

Phase 2/3 × tislelizumab × Thoracic × Clear all

NCT07131319 2026-02-02

SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC

Phase 2/3 Recruiting

Carcinoma, Non-Small-Cell Lung